How to Help Your Patients Find Merilog in Stock: A Provider's Guide

You've written the prescription for Merilog (insulin aspart-szjj). Your patient is on board. But then your office gets a call: "My pharmacy doesn't have it."

This scenario has become increasingly common since Merilog's launch. As the first rapid-acting insulin biosimilar, Merilog offers clear clinical and cost benefits — but pharmacy availability hasn't caught up with demand. This guide provides practical strategies for helping your patients navigate the current supply landscape.

Current Merilog Availability

Merilog has been commercially available since July 2025. It is not listed on the FDA or ASHP shortage databases, but real-world access varies significantly by geography, pharmacy type, and insurance coverage.

Key factors affecting availability in early 2026:

• Formulary adoption is ongoing. Many PBMs are still evaluating Merilog for formulary inclusion. Until a plan covers it, pharmacies in that network may not stock it.
• Demand surge from market shifts. The discontinuation of Novo Nordisk's unbranded insulin aspart (December 2025) and ongoing Fiasp FlexTouch pen shortages have redirected patients toward Merilog and other alternatives.
• Distribution is expanding. Sanofi is actively working to expand wholesale distribution, and availability is improving month over month.

Why Patients Can't Find Merilog

Understanding the specific barriers your patients face helps you troubleshoot more effectively:

Insurance Barriers

If a patient's insurance doesn't cover Merilog, the pharmacy may not carry it. Even if coverage exists, prior authorization requirements can delay access. Check formulary status before prescribing when possible.

Pharmacy Stocking Patterns

Chain pharmacies typically stock based on formulary agreements and patient volume. A pharmacy with few Merilog prescriptions has little reason to keep it in stock. Independent pharmacies are generally more flexible.

Geographic Variability

Availability can vary significantly between regions. Urban areas with multiple pharmacy options tend to have better access than rural communities with limited pharmacy choices.

Patient Awareness

Some patients may not know they can request their pharmacy to order it, try a different pharmacy, or use Sanofi's savings programs to bypass insurance issues entirely.

What Providers Can Do: 5 Actionable Steps

Step 1: Direct Patients to Medfinder

Medfinder allows patients — and your staff — to search for pharmacies with Merilog in stock in real time. Consider integrating this into your discharge or prescription workflow:

• Provide patients with the URL: medfinder.com
• Have your MA or nurse check availability during the visit
• Print pharmacy options for patients to take with them

Step 2: Prescribe Flexibly When Appropriate

If Merilog is your first choice but availability is uncertain:

• Send the Merilog prescription electronically and have the pharmacy confirm stock before the patient arrives
• Consider writing a backup prescription for an alternative (NovoLog, Humalog, or Admelog) in case the primary cannot be filled
• Specify both vial and pen NDCs if the patient can use either formulation

Step 3: Inform Patients About the $35 Savings Program

Many patients don't know that Sanofi's Insulins Valyou Savings Program offers all Sanofi insulins — including Merilog — for $35 per 30-day supply, regardless of insurance status. This program launched January 1, 2026 and covers:

• Merilog (insulin aspart-szjj)
• Lantus (insulin glargine)
• Toujeo (insulin glargine U-300)
• Admelog (insulin lispro)
• Apidra (insulin glulisine)

For patients without insurance or with high deductibles, this can be transformative. The program eliminates the need for prior authorization and can be used at most pharmacies. For uninsured patients with greater financial need, the Sanofi Patient Connection program may provide medication at no cost.

Step 4: Leverage Independent and Specialty Pharmacies

If chain pharmacies in your area don't stock Merilog, build relationships with independent pharmacies that are willing to order it. Specialty pharmacies that serve endocrinology patients may also have more consistent supply.

Consider maintaining a list of local pharmacies known to stock or readily order Merilog, and share it with your patients.

Step 5: Stay Current on Supply Changes

The insulin market is evolving rapidly. Stay informed about:

• Formulary changes at major insurers in your area
• New biosimilar approvals and launches
• Shortage updates from ASHP and FDA

Resources like Medfinder for providers and the ASHP drug shortage database can help you stay current.

Therapeutic Alternatives to Merilog

When Merilog is unavailable, these rapid-acting insulins are clinically appropriate alternatives for most patients:

• NovoLog (insulin aspart): The reference product. Same active ingredient as Merilog. Widely available. Vial ~$72, FlexPen carton ~$140 after Novo Nordisk's 2024 price reduction.
• Humalog (insulin lispro): Different molecule, equivalent clinical profile. Vials ~$35 after Eli Lilly's price cut. Widely available at most pharmacies.
• Admelog (insulin lispro): Sanofi's biosimilar to Humalog. Uses the same SoloStar pen as Merilog. Available for $35/month through Sanofi's Valyou program.
• Apidra (insulin glulisine): Another Sanofi rapid-acting insulin. Also $35/month through Valyou. Uses SoloStar pen.

For patients currently on Merilog SoloStar pens, Admelog SoloStar is the most seamless switch — same pen device, same manufacturer, same $35 pricing.

See our detailed comparison: Alternatives to Merilog.

Workflow Tips for Your Practice

• Add Merilog availability check to your prescription workflow. Before the patient leaves, confirm that their preferred pharmacy has stock or can order it.
• Create a Merilog patient handout. Include the Sanofi savings program phone number (1-888-847-4877), the Medfinder URL, and key talking points about the medication.
• Flag patients on Merilog in your EHR. If a shortage develops or formulary status changes, you can proactively reach out to affected patients rather than fielding reactive calls.
• Train front-desk staff. When patients call about Merilog availability, staff should know to direct them to Medfinder, suggest they ask their pharmacy to order it, and offer to send a backup prescription if needed.
• Document insurance barriers. If prior authorization is denied for Merilog, document the clinical rationale for appeals. Merilog's status as the first insulin aspart biosimilar and its cost advantages provide strong medical necessity arguments.

Final Thoughts

Merilog is a clinically sound, affordable option that benefits both patients and the healthcare system. The availability challenges are a function of market timing — not product quality. As a prescriber, you're in a unique position to bridge the gap between prescription and access.

Use Medfinder for providers to track availability, keep your patients informed about savings programs, and maintain flexible prescribing strategies. The supply picture is improving, and your proactive support makes a real difference for patients navigating this transition.

For the patient perspective on Merilog supply issues, see our 2026 shortage update for patients.